Introducing the TissueCypher™ Platform

Cernostics is focused on delivering next generation cancer diagnostic and prognostic tests through a unique approach to tissue analysis




Most current diagnostic approaches offer a limited view of cancer, because they fail to evaluate the tumor as a system composed of multiple, interacting cell types, not merely tumor cells.  Cernostics' patented technology is based on a tissue systems biology approach to anatomic pathology, the discipline of evaluating tissues by a pathologist via light microscopy.  Cernostics's tissue systems biology approach simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide, while preserving and evaluating tissue structure.


Cernostics' technology platform, called TissueCypher™, is a digital platform for multi-channel fluorescence whole slide imaging, and includes image reading, image segmentation, biomarker expression and tissue structure evaluation.


From a tissue section mounted on a single slide, the TissueCypher™ platform identifies:


  1. Tissue structure (morphology)
  2. Specific cell types within the tissue such as immune, epithelial, and stromal cell types
  3. Biomarker intensity and co-expression patterns
  4. Spatial relationships, including distributions and gradients of biomarker expression within tissue structures and cell types


Contact Us to learn more about our technology platform and how it will change the future of cancer diagnostics.

Customer Service

Mon-Fri 9am-5pm (EST)